Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial.
Paul BarrowSusan D RichmanAndrew J WallaceKelly HandleyGordon G A HutchinsDavid KerrLaura MagillD Gareth EvansRichard GrayPhil QuirkeJames HillPublished in: Histopathology (2019)
B2M mutations were detected in nearly one-third of dMMR cancers, none of which recurred. B2M mutation status has potential clinical utility as a prognostic biomarker in stage II dMMR CRC. The mechanism of protection against recurrence and whether this protection extends to stage III disease remains unclear.